| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3872647 | The Journal of Urology | 2010 | 9 Pages |
Abstract
TRAIL plus interferon-α synergistically induces apoptosis in renal cell carcinoma cells, which is due at least in part to interferon-α mediated changes in extracellular signal-regulated kinase activation. TRAIL and interferon-α combination therapy may be a novel approach to advanced renal cell carcinoma that warrants further testing in vivo.
Keywords
PARPp53 up-regulated modulator of apoptosisTNFExtracellular signal-regulated MAP kinasesXIAPc-FLIPDCRRCCFLIPPKCMTSDAPIERKPBSMCL3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium4,6-diamidino-2-phenylindolecIAPDMSOSmac/DIABLOinterferonIFNinterferonscellular Inhibitor of ApoptosisEnzyme-linked immunosorbent assayELISAdeath domainDimethyl sulfoxideVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)tumor necrosis factorPhosphate buffered salineTRAILTNF-related apoptosis-inducing ligandX-linked inhibitor of apoptosisProtein kinase Cpropidium iodinePUMARenal cell carcinomaCarcinoma, renal cellKidneyextracellular signal-regulated kinaseDecoy receptor
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Peter E. Clark, Dina A. Polosukhina, Kenneth Gyabaah, Harold L. Moses, Andrew Thorburn, Roy Zent,